Texas Oncology - Central South

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Cervical cancer2 trials
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Head and neck cancer1 trial
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• Metastatic breast cancer1 trial

Phase

• Phase 35 trials
• Phase 1/21 trial
• Phase 21 trial
• Phase 41 trial

Status

• Recruiting6 trials
• Active, not recruiting2 trials

Lead sponsor

• Pfizer5 trials
• Seagen, a wholly owned subsidiary of Pfizer2 trials
• Janssen Research & Development, LLC1 trial

Running trials

• Recruiting

  Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

  NCT07578649· Phase 3· Pfizer· Source

• Recruiting

  Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  NCT07227415· Phase 1/2· Pfizer· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

  NCT06952660· Phase 4· Pfizer· Source

• Active, not recruiting

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

  NCT04579380· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Cervical cancer1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting